Poxviridae Infections - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 96
Inquire Before Buying

Global Markets Direct's, ‘Poxviridae Infections - Pipeline Review, H2 2016', provides an overview of the Poxviridae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Poxviridae Infections , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poxviridae Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Poxviridae Infections

  • The report reviews pipeline therapeutics for Poxviridae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Poxviridae Infections therapeutics and enlists all their major and minor projects

  • The report assesses Poxviridae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Poxviridae Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Poxviridae Infections

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Poxviridae Infections pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Poxviridae Infections - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Poxviridae Infections Overview 9
Therapeutics Development 10
Pipeline Products for Poxviridae Infections - Overview 10
Pipeline Products for Poxviridae Infections - Comparative Analysis 11
Poxviridae Infections - Therapeutics under Development by Companies 12
Poxviridae Infections - Therapeutics under Investigation by Universities/Institutes 14
Poxviridae Infections - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Poxviridae Infections - Products under Development by Companies 17
Poxviridae Infections - Products under Investigation by Universities/Institutes 18
Poxviridae Infections - Companies Involved in Therapeutics Development 19
Bavarian Nordic A/S 19
BioFactura, Inc. 20
CEL-SCI Corporation 21
Chimerix, Inc. 22
China Biologic Products, Inc. 23
CJ HealthCare Corp. 24
EpiVax, Inc. 25
N & N Pharmaceuticals Inc. 26
SIGA Technologies, Inc. 27
Takeda Pharmaceutical Company Limited 28
Tonix Pharmaceuticals Holding Corp. 29
Verrica Pharmaceuticals Inc. 30
Poxviridae Infections - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
(plague + small pox) vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
24a - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
BA-368 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
brincidofovir - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
CEL-1000 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
CJ-40011 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
imatinib mesylate - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Monoclonal Antibodies for Infectious Disease - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Monoclonal Antibody for Smallpox - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
nilotinib - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
NN-001 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
PL-801 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
SCV-305 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecules for Molluscum Contagiosum - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
small pox vaccine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
smallpox vaccine - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
smallpox vaccine - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
tecovirimat - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
varicella hyperimmune globulins - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
VIR-001 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
VIR-002 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
VP-100 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Poxviridae Infections - Dormant Projects 83
Poxviridae Infections - Discontinued Products 86
Poxviridae Infections - Product Development Milestones 87
Featured News & Press Releases 87
Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government 87
Apr 25, 2016: SIGA Announces Enrollment of First Patients in the Final Cohort of Phase III Study of Tecovirimat 87
Mar 17, 2016: SIGA Commences Clinical Study for Intravenous (IV) Formulation of TPOXX 87
Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral 88
Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral 88
Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 88
Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene 89
Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox 89
Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 90
Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million 90
May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine 91
Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery 92
Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million 92
Dec 23, 2014: Chimerix Provides Recap of 2014 Events 93
Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine 94
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 95
Disclaimer 96

List of Tables

Number of Products under Development for Poxviridae Infections, H2 2016 10
Number of Products under Development for Poxviridae Infections - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Poxviridae Infections - Pipeline by Bavarian Nordic A/S, H2 2016 19
Poxviridae Infections - Pipeline by BioFactura, Inc., H2 2016 20
Poxviridae Infections - Pipeline by CEL-SCI Corporation, H2 2016 21
Poxviridae Infections - Pipeline by Chimerix, Inc., H2 2016 22
Poxviridae Infections - Pipeline by China Biologic Products, Inc., H2 2016 23
Poxviridae Infections - Pipeline by CJ HealthCare Corp., H2 2016 24
Poxviridae Infections - Pipeline by EpiVax, Inc., H2 2016 25
Poxviridae Infections - Pipeline by N & N Pharmaceuticals Inc., H2 2016 26
Poxviridae Infections - Pipeline by SIGA Technologies, Inc., H2 2016 27
Poxviridae Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 28
Poxviridae Infections - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016 29
Poxviridae Infections - Pipeline by Verrica Pharmaceuticals Inc., H2 2016 30
Assessment by Monotherapy Products, H2 2016 31
Assessment by Combination Products, H2 2016 32
Number of Products by Stage and Target, H2 2016 34
Number of Products by Stage and Mechanism of Action, H2 2016 36
Number of Products by Stage and Route of Administration, H2 2016 38
Number of Products by Stage and Molecule Type, H2 2016 40
Poxviridae Infections - Dormant Projects, H2 2016 83
Poxviridae Infections - Dormant Projects (Contd..1), H2 2016 84
Poxviridae Infections - Dormant Projects (Contd..2), H2 2016 85
Poxviridae Infections - Discontinued Products, H2 2016 86

List of Figures

Number of Products under Development for Poxviridae Infections, H2 2016 10
Number of Products under Development for Poxviridae Infections - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 16
Assessment by Monotherapy Products, H2 2016 31
Number of Products by Targets, H2 2016 33
Number of Products by Stage and Targets, H2 2016 33
Number of Products by Mechanism of Actions, H2 2016 35
Number of Products by Stage and Mechanism of Actions, H2 2016 35
Number of Products by Routes of Administration, H2 2016 37
Number of Products by Stage and Routes of Administration, H2 2016 37
Number of Products by Top 10 Molecule Types, H2 2016 39
Number of Products by Stage and Top 10 Molecule Types, H2 2016 39
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • Efficacy of Stand-alone Power Sources Drive The Global Distributed Energy Generation Market
    The global market for distributed energy generation is expected to magnify at a momentous CAGR of 11.4% between 2016 and 2020. The small-scale generation of electricity, oscillating from a few kilowatts to multitudes of megawatts, is denoted as distributed energy generation. In this process, power is usually produced using renewable resources or by generators during consumption. [...]
  • Global Organic Food Market Makes A Mark in Developed Economies
    Buyers throughout the world are becoming more and more health cognizant, which has occasioned in an alteration in their palates and inclinations. The global organic food market was worth US$88.1 billion in 2015 is anticipated to record a CAGR of over 16% between 2015 and 2020. Amongst the various different food products available, the fruits [...]
  • Global Cefazolin Sodium Market Professional Survey Report 2017
    Published: 13-Jan-2017        Price: US 3500 Onwards        Pages: 125
    Notes: Production, means the output of Cefazolin Sodium Revenue, means the sales value of Cefazolin Sodium This report studies Cefazolin Sodium in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market......
  • Global Cefazolin Sodium Sales Market Report 2017
    Published: 11-Jan-2017        Price: US 4000 Onwards        Pages: 118
    Notes: Sales, means the sales volume of Cefazolin Sodium Revenue, means the sales value of Cefazolin Sodium This report studies sales (consumption) of Cefazolin Sodium in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Acs Dobfar spa - Fresenius Kabi Anti-Infectives - Olon - Orchid......
  • Global Clotrimazole Market Professional Survey Report 2017
    Published: 10-Jan-2017        Price: US 3500 Onwards        Pages: 124
    Notes: Production, means the output of Clotrimazole Revenue, means the sales value of Clotrimazole This report studies Clotrimazole in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for e......
  • Global Clotrimazole Market Research Report 2017
    Published: 03-Jan-2017        Price: US 2900 Onwards        Pages: 110
    Notes: Production, means the output of Clotrimazole Revenue, means the sales value of Clotrimazole This report studies Clotrimazole in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering - Bayer - Erregierre - F.I.S. - Amoli Organics - CordenPharma - ......
  • Aspergillosis-Pipeline Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Aspergillosis-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Aspergillosis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, f......
  • Shigella Infections (Shigellosis)-API Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • Escherichia Coli Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Escherichia Coli Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Escherichia Coli Infections Report is to understand the market and pipeline status of the drugs around the Escherichia Coli Infections to explore the generic development opportunities, licensing opportunities an......
  • Fungal Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Jan-2017        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Fungal Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Fungal Infections Report is to understand the market and pipeline status of the drugs around the Fungal Infections to explore the generic development opportunities, licensing opportunities and to gain competitive advantag......
  • Mycamine -Drug Insights, 2017
    Published: 01-Jan-2017        Price: US 1000 Onwards        Pages: 35
    DelveInsight Drug Report, "Mycamine- Drug Insights, 2017" highlights the Mycamine marketed details, pipeline status and the Global API Manufacturers along with the location. The DelveInsight's report covers the Global Market Assessment of the Mycamine covering the total sales estimation and also provides the Mycamine sales performance during the historical period and forecast period to 2018. DelveInsight's Report also covers the detailed clinical assessment of Mycamine, patents information and e......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs